ACM
TERN

Aquatic Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Aquatic Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,000
Closed -$1.94M – 1808
2025
Q4 		$1.94M Buy
+48,000
New +$1.11M 0.06% 384
2024
Q2 		– Sell
-1,400
Closed -$9.18K – 1594
2024
Q1 		$9.18K Buy
+1,400
New +$9.14K ﹤0.01% 1145
2023
Q3 		– Sell
-2,400
Closed -$21K – 1644
2023
Q2 		$21K Buy
2,400
+2,300
+2,300% +$26.8K ﹤0.01% 1128
2023
Q1 		$1K Buy
+100
New +$956 ﹤0.01% 1198

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Aquatic Capital Management's TERN Position: Q1 2026 in Review

Aquatic Capital Management sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 48,000 shares — an estimated $1.94M sold.

Aquatic Capital Management first reported a position in TERN in Q1 2023 and held it in 4 quarters. The position peaked at $1.94M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Aquatic Capital Management reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 48,000 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.94M.
  • Aquatic Capital Management first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 4 quarters.
  • Aquatic Capital Management's Terns Pharmaceuticals position peaked at $1.94M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Aquatic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.